{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:09:24Z","timestamp":1793506164767,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Zhejiang Province Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jconrel.2026.114784","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T16:26:25Z","timestamp":1772555185000},"page":"114784","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Intravitreal delivery of LATS1 mRNA by lipid nanoparticles as an effective strategy for uveal melanoma therapy"],"prefix":"10.1016","volume":"393","author":[{"given":"Siyu","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoqi","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwen","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengchun","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanjuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sitao","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangsheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wencan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jconrel.2026.114784_bb0005","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/ICU.0000000000000366","article-title":"New concepts in the molecular understanding of uveal melanoma","volume":"28","author":"Reichstein","year":"2017","journal-title":"Curr. Opin. Ophthalmol."},{"issue":"9","key":"10.1016\/j.jconrel.2026.114784_bb0010","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/j.ophtha.2011.01.040","article-title":"Uveal melanoma: trends in incidence, treatment, and survival","volume":"118","author":"Singh","year":"2011","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.jconrel.2026.114784_bb0015","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1093\/annonc\/mdz176","article-title":"Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study","volume":"30","author":"Khoja","year":"2019","journal-title":"Anna. Oncol.\u202f: Off. J. Eur. Soci. Medi. Oncol."},{"issue":"6","key":"10.1016\/j.jconrel.2026.114784_bb0020","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1080\/01676830.2017.1337183","article-title":"Comparison of primary and secondary enucleation for uveal melanoma","volume":"36","author":"Pham","year":"2017","journal-title":"Orbit"},{"issue":"3","key":"10.1016\/j.jconrel.2026.114784_bb0025","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/ICU.0000000000000468","article-title":"Plaque brachytherapy for posterior uveal melanoma in 2018","volume":"29","author":"Reichstein","year":"2018","journal-title":"Curr. Opin. Ophthalmol."},{"issue":"6","key":"10.1016\/j.jconrel.2026.114784_bb0030","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3390\/medicina59061131","article-title":"Deterioration of visual acuity after brachytherapy and proton therapy of uveal melanoma, and methods of counteracting this complication based on recent publications","volume":"59","author":"Jarczak","year":"2023","journal-title":"Medicina"},{"issue":"2","key":"10.1016\/j.jconrel.2026.114784_bb0035","doi-asserted-by":"crossref","first-page":"72","DOI":"10.31083\/j.fbl2702072","article-title":"Liver metastasis in uveal melanoma - treatment options and clinical outcome","volume":"27","author":"Gverovi\u0107 Antunica","year":"2022","journal-title":"Front. Biosci. Landmark"},{"issue":"51","key":"10.1016\/j.jconrel.2026.114784_bb0040","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202303261","article-title":"Lipid nanoparticle (LNP) enables mRNA delivery for Cancer therapy","volume":"35","author":"Zong","year":"2023","journal-title":"Adv. Mater."},{"issue":"9","key":"10.1016\/j.jconrel.2026.114784_bb0045","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1016\/j.ymthe.2024.04.035","article-title":"mRNA-based therapeutic strategies for cancer treatment","volume":"32","author":"Taibi","year":"2024","journal-title":"Mol. Therapy\u202f: J. Am. Soc. Gene Therapy"},{"key":"10.1016\/j.jconrel.2026.114784_bb0050","doi-asserted-by":"crossref","first-page":"0178","DOI":"10.34133\/bmr.0178","article-title":"Current trends in messenger RNA Technology for Cancer Therapeutics","volume":"29","author":"Afzal","year":"2025","journal-title":"Biomaterials Research"},{"issue":"1","key":"10.1016\/j.jconrel.2026.114784_bb0055","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.apsb.2024.09.009","article-title":"Advances and prospects of RNA delivery nanoplatforms for cancer therapy","volume":"15","author":"Attia","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"issue":"12","key":"10.1016\/j.jconrel.2026.114784_bb0060","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1038\/s41596-025-01174-4","article-title":"The design, manufacture and LNP formulation of mRNA for research use","volume":"20","author":"Leighton","year":"2025","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.jconrel.2026.114784_bb0065","article-title":"Recent advances in mRNA delivery systems for cancer therapy","author":"Zhang","year":"2025","journal-title":"Adv. Sci.12 (29)"},{"issue":"22","key":"10.1016\/j.jconrel.2026.114784_bb0070","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202309917","article-title":"Design of PD-L1-targeted lipid nanoparticles to turn on PTEN for efficient cancer therapy","volume":"11","author":"Kim","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.jconrel.2026.114784_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108189","article-title":"Novel strategies exploiting interleukin-12 in cancer immunotherapy","volume":"239","author":"Cirella","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2026.114784_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113588","article-title":"Pancreas-targeted lipid nanoparticles for relatively non-invasive interleukin-12 mRNA therapy in orthotopic pancreatic ductal adenocarcinoma","volume":"381","author":"Shen","year":"2025","journal-title":"J. of Controll. Release : Off. J. Controll. Release Soc."},{"issue":"1","key":"10.1016\/j.jconrel.2026.114784_bb0085","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41392-022-01007-w","article-title":"mRNA-based therapeutics: powerful and versatile tools to combat diseases","volume":"7","author":"Qin","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"12","key":"10.1016\/j.jconrel.2026.114784_bb0090","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1039\/C7BM00712D","article-title":"A new developing class of gene delivery: messenger RNA-based therapeutics","volume":"5","author":"Meng","year":"2017","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.jconrel.2026.114784_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2023.108130","article-title":"Development and applications of mRNA treatment based on lipid nanoparticles","volume":"65","author":"Wang","year":"2023","journal-title":"Biotechnol. Adv."},{"issue":"23","key":"10.1016\/j.jconrel.2026.114784_bb0100","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1021\/acs.accounts.1c00550","article-title":"Lipid nanoparticle\u2013mRNA formulations for therapeutic applications","volume":"54","author":"Wang","year":"2021","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.jconrel.2026.114784_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbpa.2024.102499","article-title":"Rational design of lipid nanoparticles: overcoming physiological barriers for selective intracellular mRNA delivery","volume":"81","author":"Zhao","year":"2024","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.jconrel.2026.114784_bb0110","article-title":"Low-frequency ultrasound-mediated blood-brain barrier opening enables non-invasive lipid nanoparticle RNA delivery to glioblastoma","volume":"385","author":"Elbaz","year":"2025","journal-title":"J. of Controll. Release : Off. J. Controll. Release Soc."},{"key":"10.1016\/j.jconrel.2026.114784_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2025.123410","article-title":"LNPs-mediated VEGF-C mRNA delivery promotes heart repair and attenuates inflammation by stimulating lymphangiogenesis post-myocardial infarction","volume":"322","author":"Zhang","year":"2025","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2026.114784_bb0120","article-title":"mRNA-LNP vaccines against hepatitis B virus induce protective immune responses in preventive and chronic mouse challenge models","volume":"33","author":"Limeres","year":"2025","journal-title":"Mole. Therapy\u202f: J. Ame. Soci. Gene Therapy"},{"issue":"13","key":"10.1016\/j.jconrel.2026.114784_bb0125","doi-asserted-by":"crossref","first-page":"6534","DOI":"10.7150\/thno.111200","article-title":"Precision treatment of ventilator-induced lung injury through alveolar epithelial cell targeted lipid nanoparticle delivery","volume":"15","author":"Ding","year":"2025","journal-title":"Theranostics"},{"issue":"6","key":"10.1016\/j.jconrel.2026.114784_bb0130","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1021\/acs.molpharmaceut.5c00248","article-title":"Lipid nanoparticles-mediated mRNA delivery to the eye affected by ionizable cationic lipid","volume":"22","author":"Dong","year":"2025","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2026.114784_bb0135","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jconrel.2025.01.068","article-title":"Lipid nanoparticle-mediated intracameral mRNA delivery facilitates gene expression and editing in the anterior chamber of the eye","volume":"379","author":"Vasudevan","year":"2025","journal-title":"J. of Controll. Release\u202f: Off. J. Controll. Release Soc."},{"issue":"2","key":"10.1016\/j.jconrel.2026.114784_bb0140","doi-asserted-by":"crossref","first-page":"eadd4623","DOI":"10.1126\/sciadv.add4623","article-title":"Peptide-guided lipid nanoparticles deliver mRNA to the neural retina of rodents and nonhuman primates","volume":"9","author":"Herrera-Barrera","year":"2023","journal-title":"Sci. Adv."},{"issue":"3","key":"10.1016\/j.jconrel.2026.114784_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108284","article-title":"A regulation loop between YAP and NR4A1 balances cell proliferation and apoptosis","volume":"33","author":"He","year":"2020","journal-title":"Cell Rep."},{"issue":"4","key":"10.1016\/j.jconrel.2026.114784_bb0150","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1152\/physrev.00005.2014","article-title":"The biology of YAP\/TAZ: hippo signaling and beyond","volume":"94","author":"Piccolo","year":"2014","journal-title":"Physiol. Rev."},{"issue":"4","key":"10.1016\/j.jconrel.2026.114784_bb0155","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41580-018-0086-y","article-title":"Hippo-YAP\/TAZ signalling in organ regeneration and regenerative medicine","volume":"20","author":"Moya","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.114784_bb0160","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1146\/annurev-biochem-013118-111829","article-title":"The hippo pathway: biology and pathophysiology","volume":"88","author":"Ma","year":"2019","journal-title":"Annu. Rev. Biochem."},{"issue":"6","key":"10.1016\/j.jconrel.2026.114784_bb0165","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.ccr.2014.04.017","article-title":"Mutant Gq\/11 promote uveal melanoma tumorigenesis by activating YAP","volume":"25","author":"Yu","year":"2014","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.jconrel.2026.114784_bb0170","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1016\/j.celrep.2019.03.021","article-title":"YAP\/TAZ activation drives uveal melanoma initiation and progression","volume":"29","author":"Li","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.jconrel.2026.114784_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2020.100915","article-title":"Immune responses to retinal gene therapy using adeno-associated viral vectors \u2013 implications for treatment success and safety","volume":"83","author":"Bucher","year":"2021","journal-title":"Prog. Retin. Eye Res."},{"issue":"5","key":"10.1016\/j.jconrel.2026.114784_bb0180","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/med.22036","article-title":"The menace of severe adverse events and deaths associated with viral gene therapy and its potential solution","volume":"44","author":"Kachanov","year":"2024","journal-title":"Med. Res. Rev."},{"issue":"1","key":"10.1016\/j.jconrel.2026.114784_bb0185","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"7","key":"10.1016\/j.jconrel.2026.114784_bb0190","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.ymthe.2017.03.013","article-title":"Lipid nanoparticle Systems for Enabling Gene Therapies","volume":"25","author":"Cullis","year":"2017","journal-title":"Mol. Ther."},{"issue":"3","key":"10.1016\/j.jconrel.2026.114784_bb0195","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/mt.2009.281","article-title":"The use of inhibitors to study endocytic pathways of gene carriers: optimization and pitfalls","volume":"18","author":"Vercauteren","year":"2010","journal-title":"Mol. Therapy\u202f: J. Am. Soc. Gene Therapy"},{"issue":"1","key":"10.1016\/j.jconrel.2026.114784_bb0200","doi-asserted-by":"crossref","first-page":"8522","DOI":"10.1038\/s41467-025-63553-5","article-title":"Ocular delivery of lipid nanoparticles-formulated mRNA encoding lanosterol synthase ameliorates cataract in rats","volume":"16","author":"Song","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.114784_bb0205","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.2147\/DDDT.S308377","article-title":"Inhibitors targeting YAP in gastric Cancer: current status and future perspectives","volume":"15","author":"Yong","year":"2021","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.jconrel.2026.114784_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114847","article-title":"Advances of targeting the YAP\/TAZ-TEAD complex in the hippo pathway for the treatment of cancers","volume":"244","author":"Luo","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.jconrel.2026.114784_bb0215","first-page":"145","article-title":"Emerging roles for the YAP\/TAZ transcriptional regulators in brain tumour pathology and targeting options","volume":"48","author":"Strepkos","year":"2021","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.jconrel.2026.114784_bb0220","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3389\/fcell.2019.00156","article-title":"Safety considerations in the development of hippo pathway inhibitors in cancers","volume":"7","author":"Kakiuchi-Kiyota","year":"2019","journal-title":"Front. Cell Dev. Biol."},{"issue":"10432","key":"10.1016\/j.jconrel.2026.114784_bb0225","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S0140-6736(23)02444-3","article-title":"mRNA-based therapeutics: looking beyond COVID-19 vaccines","volume":"403","author":"Parhiz","year":"2024","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jconrel.2026.114784_bb0230","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.jhep.2021.08.011","article-title":"Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model","volume":"75","author":"Yang","year":"2021","journal-title":"J. Hepatol."},{"issue":"10","key":"10.1016\/j.jconrel.2026.114784_bb0235","doi-asserted-by":"crossref","first-page":"E1941","DOI":"10.1073\/pnas.1619653114","article-title":"Systemic delivery of factor IX messenger RNA for protein replacement therapy","volume":"114","author":"Ramaswamy","year":"2017","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2026.114784_bb0240","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.2147\/IJN.S452896","article-title":"Ionizable lipid nanoparticle-mediated TRAIL mRNA delivery in the tumor microenvironment to inhibit colon cancer progression","volume":"19","author":"da Silva","year":"2024","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2026.114784_bb0245","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jconrel.2019.04.015","article-title":"Lipid nanoparticles for delivery of messenger RNA to the back of the eye","volume":"303","author":"Patel","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.114784_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2024.102325","article-title":"The dynamic process of mRNA delivery by lipid nanoparticles in vivo","volume":"57","author":"Ma","year":"2024","journal-title":"Nano Today"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926001860?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926001860?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T17:01:03Z","timestamp":1781715663000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926001860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":50,"alternative-id":["S0168365926001860"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.114784","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravitreal delivery of LATS1 mRNA by lipid nanoparticles as an effective strategy for uveal melanoma therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.114784","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114784"}}